Novel hexahydrocyclopentapyrrol-indolemethanimine as highly potent α-glucosidase inhibitors; design, biological evaluation, and computational insights
Bioorganic Chemistry · 2025
DOI: 10.1016/j.bioorg.2025.108922 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2025. Verfasst von Shiva Molaei und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical and Heterocyclic Compounds Research Laboratory, Department of Chemistry, Iran; University of Science and Technology, Tehran, Iran. Hauptthemen laut MEDLINE: alpha-Glucosidases, Cyclopentanes, Drug Design, Glycoside Hydrolase Inhibitors. Die Arbeit nennt 27 Literaturangaben. Gefördert von: Vice-Chancellor for Research, Shiraz University of Medical Sciences.
Abstract (Originalsprache)
A series of novel hexahydrocyclopentapyrrol-indolemethanimine derivatives were synthesized and evaluated for their α-glucosidase inhibitory activity. All compounds demonstrated promising inhibition with IC50 values in the range of 1.05 to 95.60 μM, which compounds 9i, 9l, and 9o demonstrated the best potential anti-α-glucosidase activity (IC50 of 1.05, 14.45, and 17.13 μM, respectively), surpassing the efficacy of the positive control, acarbose (IC50 = 750.0 ± 2.0 μM). The kinetic studies showed that the most potent derivative (compound 9i) inhibits competitively, which suggests its direct interaction at the active site of α-glucosidase (Kᵢ value of 0.39 μM). Molecular docking studies demonstrated that compound 9i effectively forms hydrogen bonds and hydrophobic interactions with the enzyme active-site catalytic residues. Molecular docking studies also corroborated this idea by demonstrating that compound 9i effectively formed hydrogen bonds and hydrophobic interactions with the enzyme active-site catalytic residues. Molecular dynamics simulations further highlighted the formation and stable nature of the enzyme-inhibitor complex over a 100-ns trajectory with minimum fluctuation, suggesting strong and stable binding. These results are indicative of the fact that this new scaffold could be considered as a lead for further development of α-glucosidase inhibitors in the management of type 2 diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmaceutical and Heterocyclic Compounds Research Laboratory, Department of Chemistry, Iran; University of Science and Technology, Tehran, Iran.
- Pharmaceutical and Heterocyclic Compounds Research Laboratory, Department of Chemistry, Iran; University of Science and Technology, Tehran, Iran. Electronic address: shjavan@iust.ac.ir.
- Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences, Iran.
- Stem Cells Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address: iraji@sums.ac…
Förderung
- Vice-Chancellor for Research, Shiraz University of Medical Sciences
Zitieren
APA
Molaei, S., Javanshir, S., Mahdavi, M., & Iraji, A. (2025). Novel hexahydrocyclopentapyrrol-indolemethanimine as highly potent α-glucosidase inhibitors; design, biological evaluation, and computational insights. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2025.108922
Vancouver
Molaei S, Javanshir S, Mahdavi M, Iraji A. Novel hexahydrocyclopentapyrrol-indolemethanimine as highly potent α-glucosidase inhibitors; design, biological evaluation, and computational insights. Bioorganic Chemistry. 2025. doi:10.1016/j.bioorg.2025.108922
BibTeX
@article{Molaei2025,
author = {Molaei, Shiva and Javanshir, Shahrzad and Mahdavi, Mohammad and Iraji, Aida},
title = {Novel hexahydrocyclopentapyrrol-indolemethanimine as highly potent α-glucosidase inhibitors; design, biological evaluation, and computational insights},
journal = {Bioorganic Chemistry},
year = {2025},
doi = {10.1016/j.bioorg.2025.108922}
}
EUVIMED